3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo https://t.co/9YAmPqW44z
Links:
Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placeb…
https://www.nature.com/articles/s41591-026-04534-z
Jul-29-2026
